Page 192 - medicina-integrativa_compress

CAPÍTULO 17 ENFERMEDAD DE PARKINSON 185
11. Ratan R: Antioxidants in the treatment of neurological disease. Neuropsychopharmacol Biol Psychiatry 20:1159-1170,
In Koliatsos V, Ratan R (eds): Cell Death and Diseases of the 1996.
Nervous System. Totowa, NJ, Humana Press, 1999, p 649. 33. de Rijk MC, Breteler MM, den Breeijen JH, et al: Dietary
12. Keum YS, Jeong WS, Kong AN: Chemopreventive functions of antioxidants and Parkinson disease. The Rotterdam Study.
isothiocyanates. Drug News Prospect 18:445-451, 2005. Arch Neurol 54:762-765, 1997.
13. Karstaedt PJ, Pincus JH: Protein redistribution diet remains effective 34. Fahn S: A pilot trial of high-dose alpha-tocopherol and ascorbate in
in patients with fluctuating parkinsonism. Arch Neurol 49:149-151, early Parkinson’s disease. Ann Neurol 32:S128-S132, 1992.
1992. 35. Shoulson I: DATATOP: A decade of neuroprotective inquiry.
14. Antonini A, Leenders KL, Meier D, et al: T2 relaxation time in Parkinson Study Group. Deprenyl and Tocopherol Antioxidative
patients with Parkinson’s disease. Neurology 43:697-700, 1993. Therapy of Parkinsonism. Ann Neurol 44:S160-S166, 1998.
15. Mandel S, Maor G, Youdim MB: Iron and alpha-synuclein in 36. Zhang SM, Hernan MA, Chen H, et al: Intakes of vitamins E and C,
the substantia nigra of MPTP-treated mice: Effect of carotenoids, vitamin supplements and PD risk. Neurology
neuroprotective drugs R-apomorphine and green tea polyphenol 59:E8-E9, 2002.
(-)-epigallocatechin-3-gallate. J Mol Neurosci 24:401-416, 2004. 37. Bendon D: Selenium intake, mood and other aspects of
16. Pan T, Fei J, Zhou X, et al: Effects of green tea polyphenols on psychological functioning. Nutr Neurosci 5:363-374, 2002.
+
dopamine uptake and on MPP -induced dopamine neuron injury. 38. Pfeiffer R, Ebadi M: On the mechanism of the nullification of
Life Sci 72:1073-1083, 2003. CNS effects of L-dopa by pyridoxine in parkinsonian patients.
17. Checkoway H, Powers K, Smith-Weller T, et al: Parkinson’s disease J Neurochem 19:2175-2181, 1972.
risks associated with cigarette smoking, alcohol consumption, and 39. Eriksson T, Granerus AK, Linde A, et al: “On-off” phenomenon
caffeine intake. Am J Epidemiol 155:732-738, 2002. in Parkinson’s disease: Relationship between dopa and other
18. Clark PI, Leaverton PE: Scientific and ethical issues in the use of large neutral amino acids in plasma. Neurology 38:1245-1248,
placebo controls in clinical trials. Annu Rev Public Health 15:19-38, 1988.
1994. 40. Heller B, Fischer E, Martin R: Therapeutic action of
19. Olanow CW, Goetz CG, Kordower JH, et al: A double-blind D-phenylalanine in Parkinson’s disease. Arzneimittleforschung
controlled trial of bilateral fetal nigral transplantation in Parkinson’s 26:577-579, 1976.
disease. Ann Neurol 54:403-414, 2003. 41. Lemoine P, Robelin N, Sebert P, Mouret J: L-tyrosine: A long-term
20. De Kloet ER: Hormones, brain, and stress. Endocr Regul 37:51-68, treatment of Parkinson’s disease. C R Acad Sci 309:43-47, 1989.
2003. 42. Auddy B, Ferreira M, Blasina F, et al: Screening of antioxidant
21. Charlett A, Dobbs RJ, Purkiss AG, et al: Cortisol is higher in activity of three Indian medicinal plants, traditionally used for the
parkinsonism and is associated with gait deficit. Acta Neurol Scand management of neurodegenerative diseases. J Ethnopharmacol
97:77-85, 1998. 84:131-138, 2003.
22. Kidd PM: Neurodegeneration from mitochondrial insufficiency: 43. An alternative medicine treatment for Parkinson’s disease: Results of
Nutrients, stem cells, growth factors, and prospects for brain a multicenter clinical trial. HP-200 in Parkinson’s Disease Study
rebuilding using integrative management. Altern Med Rev 10: Group. J Altern Complement Med 1:249-255, 1995.
268-293, 2005. 44. Kim MS, Lee JI, Lee WY, et al: Neuroprotective effect of Ginkgo
23. Turunen M, Olsson J, Dallner G: Metabolism and function of biloba L. extract in a rat model of Parkinson’s disease. Phytother Res
coenzyme Q. Biochim Biophys Acta 1660:171-199, 2004. 18:663-666, 2004.
24. Shults CW, Oakes D, Kieburtz K, et al: Effects of coenzyme Q 10 45. Van Kampen J, Robertson H, Hagg T, et al: Neuroprotective actions
in early Parkinson disease: Evidence of slowing of the functional of the ginseng extract G115 in two rodent models of Parkinson’s
decline. Arch Neurol 59:1541-1550, 2002. disease. Exp Neurol 184:521-529, 2003.
25. Wright JV: Interview: Alzheimer’s, Parkinson’s, NADH research. 46. Crosby NJ, Deane KH, Clarke CE, et al: Amantadine for dyskinesia
Jorg Birkmayer, MD. Nutr Healing May:5-6, 1997. in Parkinson’s disease. Cochrane Database Syst Rev (2)CD003467,
26. Dizdar N, Kagedal B, Lindvall B: Treatment of Parkinson’s disease 2003.
with NADH. Acta Neurol Scand 90:345-347, 1994. 47. Shoulson I, DATATOP: A decade of neuroprotective inquiry.
27. Birkmayer JG, Vrecko C, Volc D, et al: NADH—a new therapeutic Ann Neurol 44(Suppl):S160, 1998.
approach to Parkinson’s disease: Comparison of oral and parenteral 48. Siderowf A, Stern M: Clinical trials with rasagiline: Evidence for
absorption. Acta Neurol Scand Suppl 146:32-35, 1993. short-term and long-term effects. Neurology 66 (Suppl 4):S80-S88,
28. Nicotinamide adenine dinucleotide (NADH): 2006.
www.naturaldatabase.com. 49. Demarcaida JA, Schwid SR, White WB, et al: Effects of tyramine
29. Coimbra CG, Junqueira VB: High doses of riboflavin and the administration in Parkinson’s disease patients treated with selective
elimination of dietary red meat promote the recovery of some MAO-B inhibitor rasagiline. Mov Disord 21:1716-1721, 2006.
motor functions in Parkinson’s disease patients. Braz J Med Biol Res 50. Blin J, Bonnett AM, Agid Y: Does levodopa aggravate Parkinson’s
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
36:1409-1417, 2003. disease? Neurology 38:1410, 1998.
30. Spencer JP, Jenna P, Daniel SE, et al: Conjugates of catecholamines 51. Fahn S, and the Parkinson Study Group: Does levodopa slow or
with cysteine and GSH in Parkinson’s disease: Possible mechanisms hasten the rate of progression of Parkinson’s disease? J Neurol
of formation involving reactive oxygen species. J Neurochem 5:2112, 252(Suppl 4):IV37–IV42, 2005.
1998. 52. Capildeo R: Implications of the 5-year CR FIRST trial. Sinemet CR
31. Funfgeld EW, Baggen M, Nedwidek P, et al: Double-blind study Five-Year International Response Fluctuation Study. Neurology
with phosphatidylserine (PS) in parkinsonian patients with senile 50(Suppl 6):S15-S17, 1998.
dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res 317: 53. The Deep-Brain Stimulation for Parkinson’s Disease Study Group:
1235-1246, 1989. Deep-brain stimulation of the subthalamic nucleus or the pars
32. Sechi G, Deledda MG, Bua G, et al: Reduced intravenous interna of the globus pallidus in Parkinson’s disease. N Engl J Med
glutathione in the treatment of early Parkinson’s disease. Prog 345:956-963, 2001.